Xianmin Zeng, a researcher and associate professor at the Buck Institute for Research on Aging, has derived 10 induced pluripotent stem cells (iPSC) lines from patients suffering from Parkinson’s Disease. Zeng will be placing those lines, and related genomic information into an NIH-approved facility for use by the larger research facility. While the population ages, the scientific community still lacks a fundamental understanding of how the disease develops on the molecular level, something Zeng’s work will hopefully begin to address.
“We think this is the largest collection of patient-derived lines generated at an academic institute,” said Zeng, who is also developing a stem cell replacement therapy for Parkinson’s Disease. “We believe the lines and the datasets we have generated from them will be a valuable resource for use in modeling PD and for the development of new therapeutics.”